News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 18, 2023, 09:00 ET Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from the second of three Phase 3 clinical studies...

Sep 13, 2023, 11:00 ET AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"

AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships. Following this...

Sep 12, 2023, 08:30 ET AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment ...

Sep 08, 2023, 11:23 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable November ...
Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs

Sep 06, 2023, 08:45 ET Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs

Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the next chapter of the BOTOX® Cosmetic and IFundWomen grant program with the...

Sep 06, 2023, 08:00 ET AbbVie to Present at the Morgan Stanley Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. Robert A....

Aug 30, 2023, 09:00 ET Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc ...

Aug 28, 2023, 08:45 ET AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted...

Aug 17, 2023, 02:00 ET AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults

AQUIPTA® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union...
Allergan Aesthetics Announces First Ever JUVÉDERM® Day

Aug 01, 2023, 08:45 ET Allergan Aesthetics Announces First Ever JUVÉDERM® Day

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes ...

Jul 27, 2023, 07:38 ET AbbVie Reports Second-Quarter 2023 Financial Results

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; ...

Jul 26, 2023, 09:00 ET AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical ...

Jul 26, 2023, 08:05 ET SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study

An open-label, efficacy assessor-blinded study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with...

Jul 24, 2023, 08:05 ET AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa

AbbVie (NYSE: ABBV) today announced that the first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ®) in adults ...

Jul 21, 2023, 04:30 ET AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

If approved, epcoritamab (TEPKINLY®) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the...

Jul 18, 2023, 22:00 ET AbbVie Employees Volunteer to Make an Impact on over 1,300 Lives in Asia with 8th Annual "Week of Possibilities" to Support Local Communities

AbbVie employees in Asia participated in its eighth annual Week of Possibilities (WOP) volunteering program, which unites employees around the world...

Jul 06, 2023, 08:00 ET AbbVie to Host Second-Quarter 2023 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023, before the market opens. AbbVie will host a...

Jun 27, 2023, 18:50 ET AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™ NHL-1 ...

Jun 26, 2023, 08:00 ET AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally

AbbVie kicks off its eighth Week of Possibilities today with more than 14,000 employees volunteering in more than 50 countries and territories to...

Jun 23, 2023, 08:04 ET AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a...

Jun 22, 2023, 13:13 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable August...

Jun 15, 2023, 08:45 ET Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated...

Jun 13, 2023, 08:45 ET BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program

Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the 20 incredible women entrepreneurs who will receive funding and mentorship...

Jun 09, 2023, 03:00 ET AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of...

Jun 06, 2023, 08:00 ET AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael,...